Braveheart Bio Raises $382.5M in U.S. IPO to Battle Heart Disease
Heart disease-focused biotech Braveheart Bio has raised $382.5 million in its U.S. IPO. Investor Demand Beats Expectations The San Francisco-based ...
Agomab Therapeutics Nv (AGMB)
This company is not actively trading or the ticker does belong to another company in our database now.
News See All
Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?
TheFly reported on June 22 that H.C. Wainwright initiated coverage of AGMB with a Buy rating and assigned a $35 price target.
8 Best Up and Coming Pharmaceutical Stocks to Buy Now
Investors looking for substantial potential without making a sizable initial investment continue to be drawn to inexpensive stocks.
7 Best Strong Buy European Stocks to Invest In
European stocks are getting a closer look as investors search beyond the crowded parts of the U.S.
Hedge Fund Resource Center